Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

Clinical trial NCT05864534 · RECRUITING

Trial details

NCT number: NCT05864534
Sponsor: Northwestern University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Newly Diagnosed Glioblastoma Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype Gliosarcoma Glioblastoma Multiforme

Start date: 2024-01-19
Primary completion: 2031-07-31
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.